Commercial Credit Report for Xcell Therapeutics Inc

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Xcell Therapeutics Inc is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Xcell Therapeutics Inc
333, Yeongdongdae-ro, Gangnam-gu
Phone: +82 28631331p:+82 28631331	SEOUL, 06188 South Korea	Ticker: 373110373110

Business Summary

XCell Therapeutics Inc is a Korea-based company mainly engaged in the development and manufacture of cell culture medium. The Company mainly conducts research, development and production of cell culture media, a material for biopharmaceuticals.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2024	12/31/2023	-	-	-	-	-

Industries

SIC Code	Description
2836	Biological products, except diagnostic substances

General Information

Outstanding Shares:	10,918,462	(As of 8/5/2024)
Stock Exchange:	KDQ
Fax Number:	+82 28630832
Email Address:	xcell@xcell.co.kr

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN